Patents Examined by Christine J. Saoud
  • Patent number: 10800842
    Abstract: An anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold, pharmaceutical compositions containing them and uses therefor.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: October 13, 2020
    Assignee: ADRENOMED AG
    Inventor: Andreas Bergmann
  • Patent number: 10800843
    Abstract: The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: October 13, 2020
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Kalyani Mondal, Betty Chan Li, Yu Chen, Taruna Arora, Hugo Matern, Wenyan Shen
  • Patent number: 10793637
    Abstract: The present disclosure relates to anti-CD39 antibodies, and antigen binding portions thereof and their use in treating cancer.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: October 6, 2020
    Assignee: Surface Oncology, Inc.
    Inventors: Scott Chappel, Andrew Lake, Michael Warren, Austin Dulak, Erik Devereaux, Pamela M. Holland, Tauqeer Zaidi, Matthew Rausch, Bianka Prinz, Nels P. Nielson, Sonia Das
  • Patent number: 10787497
    Abstract: The present invention relates to a cancer treatment composition for inhibiting angiogenesis, and a preparation method therefor. An angiogenesis inhibitor according to the present invention is a cancer treatment composition comprising a fusion protein comprising a vascular endothelial growth factor-binding domain of vascular endothelial growth factor receptor 1 (VEGFR1) and a b1 domain of neuropilin-1 (NRP1). The novel fusion protein is an angiogenesis inhibitor for blocking the binding of VEGF to a receptor in the cell membrane, and has an effect of inhibiting the proliferation of cancer cells and the growth and metastasis of cancer. In addition, the fusion protein can be used as an anti-cancer agent and exhibits an effective anti-cancer effect at a lower dose than that of a conventional angiogenesis inhibitor.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: September 29, 2020
    Assignee: IBENTRUS, INC.
    Inventors: Hoeon Kim, Hyun-ju Lee
  • Patent number: 10780121
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: September 22, 2020
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Patent number: 10781253
    Abstract: The present disclosure provides binding agents that modulate the interaction between LEAP2 and GHSR. Specifically, the present disclosure provides binding agents, such as LEAP2 peptides that bind GHSR and methods of their use to treat, ameliorate, or prevent a neuroendocrine and/or metabolic disease or disorder such as obesity, diabetes, acromegaly, gigantism and/or Prader-Willi syndrome. The present disclosure also provides binding agents, such as antibodies, that bind LEAP2, and methods of their use, to treat, ameliorate, or prevent a neuroendocrine and/or metabolic disease or disorder such as cachexia, anorexia, or other wasting syndromes.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: September 22, 2020
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Daniel David Kaplan, Xuecai Ge, Hui Tian
  • Patent number: 10765759
    Abstract: The present disclosure provides methods of treating an ocular disease or disorder. The methods involve direct administration into the eye of a conjugate comprising a biologically active polypeptide and a biocompatible polymer.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: September 8, 2020
    Assignee: The Regents of the University of California
    Inventors: Kevin E. Healy, Eda Isil Altiok, David V. Schaffer, Wesley M. Jackson
  • Patent number: 10766952
    Abstract: The present invention relates to methods for selecting a headache patient responsive to treatment with an anti-CGRP antibody and to methods for reducing headache frequency in the selected patient comprising administering an anti-CGRP antibody.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: September 8, 2020
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Rami Burstein
  • Patent number: 10758590
    Abstract: The invention relates to methods of using variants and fusions of fibroblast growth factor 19 (FGF19) for treating diabetes.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: September 1, 2020
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Patent number: 10758560
    Abstract: Neuregulin-1 (NRG1) or a fragment thereof or vitamin B12 for use in maintaining or increasing muscle function and/or mass in an ageing subject, and/or substantially preventing or reducing muscle wasting in an ageing subject.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: September 1, 2020
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Alice Pannerec, Jerome Feige
  • Patent number: 10751389
    Abstract: The present invention relates to a p75NTR neurotrophin binding protein, p75NTR(NBP), for use in the treatment of pain and/or a symptom of pain.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: August 25, 2020
    Assignee: Levicept LLD
    Inventor: Simon Westbrook
  • Patent number: 10751391
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: August 25, 2020
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Patent number: 10744184
    Abstract: Disclosed are methods of altering metabolism of phosphate in a livestock via an antibody. The methods involve the development of an antibody against FGF-23 for the purpose of reducing phosphate excretion by an animal.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: August 18, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Mark E. Cook, Elizabeth A. Bobeck, Kimberly S. Burgess
  • Patent number: 10744185
    Abstract: Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FG-F19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). In some embodiments, these variants and fusions modulate bile acid homeostasis, and are useful in treatment of bile acid related and associated disorders. In some embodiments, these variants and fusions have glucose lowering activity, and are useful in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: August 18, 2020
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo, Hui Tian
  • Patent number: 10744191
    Abstract: The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: August 18, 2020
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Kalyani Mondal, Betty Chan Li, Yu Chen, Taruna Arora, Hugo Matern, Wenyan Shen
  • Patent number: 10736874
    Abstract: A method for treating pain experienced by patients with sickle cell disease.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 11, 2020
    Inventor: Shahin Fatholahi
  • Patent number: 10738128
    Abstract: The present disclosure relates to anti-CD39 antibodies, and antigen binding portions thereof and their use in treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 11, 2020
    Assignee: Surface Oncology, Inc.
    Inventors: Scott Chappel, Andrew Lake, Michael Warren, Austin Dulak, Erik Devereaux, Pamela M. Holland, Tauqeer Zaidi, Matthew Rausch, Bianka Prinz, Nels P. Nielson, Sonia Das
  • Patent number: 10729746
    Abstract: The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant PLGF protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset. The present invention also provides exemplary recombinant PLGF proteins including monomeric, dimeric and single-chain PLGF proteins.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: August 4, 2020
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Angela Norton, Michael F. Concino, Muthuraman Meiyappan, Andrea Iskenderian
  • Patent number: 10730940
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: August 4, 2020
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • Patent number: 10729781
    Abstract: Isolated or recombinant anti-LGR4 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: August 4, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Qingyun Liu, Xing Gong, Kendra Carmon